Literature DB >> 6221606

Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins.

A Bennett, D A Berstock, M A Carroll, I F Stamford, A J Wilson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221606

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Leukot Res        ISSN: 0732-8141


× No keyword cloud information.
  7 in total

1.  Prognostic value of prostaglandin F2 alpha concentrations in breast carcinoma.

Authors:  P A van Dam; I B Vergote; G M Laekeman; G H Keersmaeckers; F L Uyttenbroeck; A G Herman
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Prospects for the future in the management of carcinoma of the breast: the biological fall out from clinical trials.

Authors:  M Baum
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

Review 3.  The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer.

Authors:  Sarah L Horn; Ian S Fentiman
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-17

Review 4.  Celecoxib in breast cancer prevention and therapy.

Authors:  Jieqing Li; Qiongyu Hao; Wei Cao; Jaydutt V Vadgama; Yong Wu
Journal:  Cancer Manag Res       Date:  2018-10-26       Impact factor: 3.989

Review 5.  Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.

Authors:  Mariana Segovia-Mendoza; Janice García-Quiroz; Lorenza Díaz; Rocío García-Becerra
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

6.  Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.

Authors:  C Benedetto; M Zonca; A M Tavella; E Petitti; M Massobrio; S Nigam; T F Slater
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

7.  Prostaglandin F2 alpha in benign and malignant breast tumours.

Authors:  I B Vergote; G M Laekeman; G H Keersmaekers; F L Uyttenbroeck; J S Vanderheyden; G P Albertyn; C F Haensch; G J De Roy; A G Herman
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.